Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Porras

Showing results (31-40 of 71) with videos related to

Pageof 8
Sort By:
Clinical Drug Investigation|May 26, 2007
Pharmacokinetic considerations in determining the terminal elimination half-lives of bisphosphonatesKenneth C Lasseter, Arturo G Porras, Andrew Denker, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|December 1, 1992
[Ocular toxoplasmosis as the first manifestation of HIV infection. Presentation of a case]P Roig, G Porras, J M Cuadrado, et al.
Anales De Medicina Interna (Madrid, Spain : 1984)|August 1, 1996
[Ocular toxoplasmosis in human immunodeficiency virus infected patients without concurrent central nervous system infection. Report of two cases]A Ortí, P Roig, E Chipont, et al.
Journal of Pediatric Surgery|December 11, 1999
Clinical recognition and management of pediatric blunt abdominal trauma without ultrasound or computed tomography scan in community hospitals in MexicoG Porras-Ramírez, F Ramírez-Reyes, M H Hernández-Herrera, et al.
Journal of Pharmaceutical and Biomedical Analysis|April 1, 1994
Determination of L-691,121, a new class III antiarrhythmic, and its principal metabolite in plasma by differential radioimmunoassayT F Greber, T V Olah, J D Gilbert, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|January 1, 1993
Clinical pharmacology of alendronate sodiumB J Gertz, S D Holland, W F Kline, et al.
The Journal of Biological Chemistry|December 10, 1983
Ligand binding to heme proteins. An evaluation of distal effectsM P Mims, A G Porras, J S Olson, et al.
Revista De Investigacion Clinica; Organo Del Hospital De Enfermedades De La Nutricion|October 1, 1987
[Prolonged vascular access for hematological treatments: experience in the city of Puebla]M A Mercado, G J Ruiz-Argüelles, A Marín López, et al.
Clinical Pharmacokinetics|March 1, 1992
Pharmacokinetics and dose proportionality of D2-agonist MK-458 (HPMC) in parkinsonismN R Cutler, S A Reines, L F McLean, et al.
Chemical Communications (Cambridge, England)|April 27, 2018
O-O bond cleavage via electrochemical reduction of a side-on peroxo dicopper model of hemocyaninI López, A G Porras-Gutiérrez, B Douziech, et al.
Pageof 8

Showing results (31-40 of 71) with videos related to

Sort By:
Pageof 8
Clinical Drug Investigation|May 26, 2007
Pharmacokinetic considerations in determining the terminal elimination half-lives of bisphosphonatesKenneth C Lasseter, Arturo G Porras, Andrew Denker, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|December 1, 1992
[Ocular toxoplasmosis as the first manifestation of HIV infection. Presentation of a case]P Roig, G Porras, J M Cuadrado, et al.
Anales De Medicina Interna (Madrid, Spain : 1984)|August 1, 1996
[Ocular toxoplasmosis in human immunodeficiency virus infected patients without concurrent central nervous system infection. Report of two cases]A Ortí, P Roig, E Chipont, et al.
Journal of Pediatric Surgery|December 11, 1999
Clinical recognition and management of pediatric blunt abdominal trauma without ultrasound or computed tomography scan in community hospitals in MexicoG Porras-Ramírez, F Ramírez-Reyes, M H Hernández-Herrera, et al.
Journal of Pharmaceutical and Biomedical Analysis|April 1, 1994
Determination of L-691,121, a new class III antiarrhythmic, and its principal metabolite in plasma by differential radioimmunoassayT F Greber, T V Olah, J D Gilbert, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|January 1, 1993
Clinical pharmacology of alendronate sodiumB J Gertz, S D Holland, W F Kline, et al.
The Journal of Biological Chemistry|December 10, 1983
Ligand binding to heme proteins. An evaluation of distal effectsM P Mims, A G Porras, J S Olson, et al.
Revista De Investigacion Clinica; Organo Del Hospital De Enfermedades De La Nutricion|October 1, 1987
[Prolonged vascular access for hematological treatments: experience in the city of Puebla]M A Mercado, G J Ruiz-Argüelles, A Marín López, et al.
Clinical Pharmacokinetics|March 1, 1992
Pharmacokinetics and dose proportionality of D2-agonist MK-458 (HPMC) in parkinsonismN R Cutler, S A Reines, L F McLean, et al.
Chemical Communications (Cambridge, England)|April 27, 2018
O-O bond cleavage via electrochemical reduction of a side-on peroxo dicopper model of hemocyaninI López, A G Porras-Gutiérrez, B Douziech, et al.
Pageof 8